Detalhe da pesquisa
1.
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
Nature
; 629(8011): 443-449, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38658754
2.
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Nature
; 543(7647): 733-737, 2017 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28329763
3.
A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.
Bioorg Med Chem Lett
; 59: 128577, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065232
4.
Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects.
Xenobiotica
; 50(2): 150-169, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31006307
5.
Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization.
Bioorg Med Chem
; 20(22): 6770-89, 2012 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23018093
6.
Preclinical Evaluation of [11C]YC-72-AB85 for In Vivo Visualization of Heat Shock Protein 90 in Brain and Cancer with Positron Emission Tomography.
ACS Chem Neurosci
; 12(20): 3915-3927, 2021 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597516
7.
Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800.
Br J Haematol
; 147(3): 319-27, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19686236
8.
Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I.
Bioorg Med Chem Lett
; 19(15): 4014-7, 2009 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19560355
9.
Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes.
ChemMedChem
; 14(14): 1305-1314, 2019 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31066983
10.
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Clin Cancer Res
; 25(10): 3164-3175, 2019 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30674502
11.
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Breast Cancer Res
; 10(2): R33, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18430202
12.
Entry into a new class of protein kinase inhibitors by pseudo ring design.
Bioorg Med Chem Lett
; 18(3): 897-900, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18248988
13.
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
J Med Chem
; 61(18): 8120-8135, 2018 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30137981
14.
Targeting Hsp90 for the treatment of cancer.
Curr Opin Drug Discov Devel
; 9(4): 483-95, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16889231
15.
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
Biochem J
; 374(Pt 3): 639-46, 2003 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12816539
16.
Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking.
J Med Chem
; 46(13): 2656-62, 2003 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-12801229
17.
Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.
J Med Chem
; 45(9): 1741-7, 2002 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-11960485
18.
Development and implementation of a highly miniaturized confocal 2D-FIDA-based high-throughput screening assay to search for active site modulators of the human heat shock protein 90beta.
J Biomol Screen
; 9(7): 569-77, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15475476
19.
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Cancer Res
; 71(15): 5255-64, 2011 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21697284
20.
Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.
Mol Cancer Ther
; 9(4): 906-19, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20371713